July 18, 2016 / 8:37 PM / a year ago

BRIEF-Cynapsus announces positive phase 3 results for Parkinson's drug

July 18 (Reuters) - Cynapsus Therapeutics Inc

* Top-Line CTH-300 results expected in late Q3 or early Q4

* New drug application for CTH-300 and CTH-301 with FDA expected to be submitted in first half of 2017.

* Cynapsus Therapeutics announces positive phase 3 dose titration phase results with APL-130277 for the treatment of off episodes in patients with Parkinson’s disease

* APL-130277 was well tolerated Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below